Keywords
Anhedonia
Taste blunting
Categories
Data Availability Statement
Not applicable
How to Cite
Abstract
Background Major depressive disorder (MDD) is a globally prevalent condition characterized by high heterogeneity. Anhedonia—the inability to experience pleasure—is a core symptom and a predictor of poor prognosis. Emerging evidence suggests that "taste blunting" (reduced taste sensitivity and pleasure) is a measurable sensory component of anhedonia, reflecting a potential disruption in the neural systems that translate sensory signals into hedonic experiences. Methods This review synthesizes current clinical and preclinical evidence to investigate the link between taste dysfunction and the brain's reward system in depression. We analyze neuroimaging data, molecular studies on taste receptors, and the impact of neuroinflammation and neurotransmitter dysregulation on the taste-reward neural circuitry. Results Clinical findings demonstrate that MDD patients exhibit significant reductions in taste intensity and pleasure, which correlate with symptom severity. Neurobiologically, this dysfunction is mapped onto a remodeled mesocorticolimbic reward circuit, involving the nucleus accumbens (NAc), ventral tegmental area (VTA), and prefrontal cortex (PFC). Molecularly, chronic stress leads to the downregulation of peripheral sweet taste receptors and 5-HT receptors in taste cells. Centrally, pro-inflammatory cytokines disrupt dopamine synthesis and corticostriatal connectivity. Furthermore, the activation of "anti-reward" systems, such as the κ-opioid receptor (KOR) system, and imbalances in glutamatergic signaling further exacerbate circuit dysfunction. Conclusions Taste blunting in depression is not a mere peripheral sensory deficit but an external manifestation of a profound disruption within the shared taste-reward neural circuitry. This perspective suggests that sensory assessment of taste may serve as a valuable translational marker for MDD subtypes. Future therapeutic strategies should move beyond monoamine-centric models to target this circuitry directly via glutamatergic modulators, KOR antagonists, and anti-inflammatory interventions.
References
[1] Su YA, Si T. Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder. Gen Psychiatr 2022;35(1):e100724. doi:10.1136/gpsych-2021-100724
[2] Serretti A. Anhedonia and Depressive Disorders. Clin Psychopharmacol Neurosci 2023;21(3):401-409. doi:10.9758/cpn.23.1086
[3] Wu C, Mu Q, Gao W, Lu S. The characteristics of anhedonia in depression: a review from a clinically oriented perspective. Transl Psychiatry 2025;15(1):90. doi:10.1038/s41398-025-03310-w
[4] Li J, Chen B, Wang Q, Xu D, Lu H, Lin G, et al. Chemosensory anhedonia facilitates depressive symptoms and cognitive impairment in late-life depression. Geriatr Gerontol Int 2024;24(10):1022-1029. doi:10.1111/ggi.14968
[5] Fitzgerald PJ. Gray colored glasses: is major depression partially a sensory perceptual disorder?. J Affect Disord 2013;151(2):418-422. doi:10.1016/j.jad.2013.06.045
[6] Steiner JE, Lidar-Lifschitz D, Perl E. Taste and odor: reactivity in depressive disorders, a multidisciplinary approach. Percept Mot Skills 1993;77(3 Pt 2):1331-46. doi:10.2466/pms.1993.77.3f.1331
[7] Höflich A, Michenthaler P, Kasper S, Lanzenberger R. Circuit Mechanisms of Reward, Anhedonia, and Depression. Int J Neuropsychopharmacol 2019;22(2):105-118. doi:10.1093/ijnp/pyy081
[8] Coccurello R. Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing. Behav Brain Res 2019;372:112041. doi:10.1016/j.bbr.2019.112041
[9] Biselli T, Lange SS, Sablottny L, Steffen J, Walther A. Optogenetic and chemogenetic insights into the neurocircuitry of depression-like behaviour: A systematic review. Eur J Neurosci 2021;53(1):9-38. doi:10.1111/ejn.14603
[10] Heshmati M, Russo SJ. Anhedonia and the brain reward circuitry in depression. Curr Behav Neurosci Rep 2015;2(3):146-153. doi:10.1007/s40473-015-0044-3
[11] Heath TP, Melichar JK, Nutt DJ, Donaldson LF. Human taste thresholds are modulated by serotonin and noradrenaline. J Neurosci 2006;26(49):12664-71. doi:10.1523/JNEUROSCI.3459-06.2006
[12] Smith SA, Trotter PD, McGlone FP, Walker SC. Effects of Acute Tryptophan Depletion on Human Taste Perception. Chem Senses 2021;46. doi:10.1093/chemse/bjaa078
[13] Thomas J, Al-Mesaabi W, Bahusain E, Mutawa M. The relationship between taste sensitivity to phenylthiocarbamide and anhedonia. Psychiatry Res 2014;215(2):444-7. doi:10.1016/j.psychres.2013.11.026
[14] Dichter GS, Smoski MJ, Kampov-Polevoy AB, Gallop R, Garbutt JC. Unipolar depression does not moderate responses to the Sweet Taste Test. Depress Anxiety 2010;27(9):859-63. doi:10.1002/da.20690
[15] Naudin M, Mondon K, El-Hage W, Perriot E, Boudjarane M, Desmidt T, et al. Taste identification used as a potential discriminative test among depression and Alzheimer׳s disease in elderly: A pilot study. Psychiatry Res 2015;228(2):228-32. doi:10.1016/j.psychres.2015.03.021
[16] Admon R, Pizzagalli DA. Dysfunctional Reward Processing in Depression. Curr Opin Psychol 2015;4:114-118. doi:10.1016/j.copsyc.2014.12.011
[17] Treadway MT, Zald DH. Parsing Anhedonia: Translational Models of Reward-Processing Deficits in Psychopathology. Curr Dir Psychol Sci 2013;22(3):244-249. doi:10.1177/0963721412474460
[18] Wang S, Leri F, Rizvi SJ. Anhedonia as a central factor in depression: Neural mechanisms revealed from preclinical to clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 2021;110:110289. doi:10.1016/j.pnpbp.2021.110289
[19] Yang AK, Mendoza JA, Lafferty CK, Lacroix F, Britt JP. Hippocampal Input to the Nucleus Accumbens Shell Enhances Food Palatability. Biol Psychiatry 2020;87(7):597-608. doi:10.1016/j.biopsych.2019.09.007
[20] Belujon P, Grace AA. Dopamine System Dysregulation in Major Depressive Disorders. Int J Neuropsychopharmacol 2017;20(12):1036-1046. doi:10.1093/ijnp/pyx056
[21] Pannu A, Goyal RK. The Potential Role of Dopamine Pathways in the Pathophysiology of Depression: Current Advances and Future Aspects. CNS Neurol Disord Drug Targets 2025;24(5):340-352. doi:10.2174/0118715273357909241126064951
[22] Pizzagalli DA. Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?. Am J Psychiatry 2022;179(7):458-469. doi:10.1176/appi.ajp.20220423
[23] Zhao X, Wu S, Li X, Liu Z, Lu W, Lin K, et al. Common neural deficits across reward functions in major depression: a meta-analysis of fMRI studies. Psychol Med 2024;54(11):2794-2806. doi:10.1017/S0033291724001235
[24] Geugies H, Groenewold NA, Meurs M, Doornbos B, de Klerk-Sluis JM, van Eijndhoven P, et al. Decreased reward circuit connectivity during reward anticipation in major depression. Neuroimage Clin 2022;36:103226. doi:10.1016/j.nicl.2022.103226
[25] Yang X, Su Y, Yang F, Song Y, Yan J, Luo Y, et al. Neurofunctional mapping of reward anticipation and outcome for major depressive disorder: a voxel-based meta-analysis. Psychol Med 2022:1-14. doi:10.1017/S0033291722002707
[26] Bekhbat M, Li Z, Mehta ND, Treadway MT, Lucido MJ, Woolwine BJ, et al. Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol Psychiatry 2022;27(10):4113-4121. doi:10.1038/s41380-022-01715-3
[27] Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry 2016;21(10):1358-65. doi:10.1038/mp.2015.168
[28] McCabe C, Harwood J, Brouwer S, Harmer CJ, Cowen PJ. Effects of pramipexole on the processing of rewarding and aversive taste stimuli. Psychopharmacology (Berl) 2013;228(2):283-90. doi:10.1007/s00213-013-3033-9
[29] Frank GK, Shott ME, Hagman JO, Mittal VA. Alterations in brain structures related to taste reward circuitry in ill and recovered anorexia nervosa and in bulimia nervosa. Am J Psychiatry 2013;170(10):1152-60. doi:10.1176/appi.ajp.2013.12101294
[30] Yoshida Y, Miyazaki M, Yajima Y, Toyoda A. Subchronic and mild social defeat stress downregulates peripheral expression of sweet and umami taste receptors in male mice. Biochem Biophys Res Commun 2021;579:116-121. doi:10.1016/j.bbrc.2021.09.063
[31] Wang Z, Zhang M, Huang M, Zhang L, Han G, Li G, et al. Effects of chronic unpredictable mild stress-induced depression on bitter taste receptor expression in mice. Arch Oral Biol 2025;169:106099. doi:10.1016/j.archoralbio.2024.106099
[32] Takahata Y, Yoshimoto W, Kuwagaki E, Yamada Y, Nagasawa K. Alteration of sweet taste receptor expression in circumvallate papillae of mice with decreased sweet taste preference induced by social defeat stress. J Nutr Biochem 2022;107:109055. doi:10.1016/j.jnutbio.2022.109055
[33] Kim D, Chung S, Lee SH, Koo JH, Lee JH, Jahng JW. Decreased expression of 5-HT1A in the circumvallate taste cells in an animal model of depression. Arch Oral Biol 2017;76:42-47. doi:10.1016/j.archoralbio.2017.01.005
[34] Kagan D, Batabyal A, Rivi V, Lukowiak K. A change in taste: the role of microRNAs in altering hedonic value. J Exp Biol 2022;225(3). doi:10.1242/jeb.243840
[35] Bekhbat M, Treadway MT, Felger JC. Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications. Curr Top Behav Neurosci 2022;58:397-419. doi:10.1007/7854_2021_294
[36] Felger JC. The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications. Curr Top Behav Neurosci 2017;31:199-219. doi:10.1007/7854_2016_13
[37] Felger JC, Treadway MT. Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. Neuropsychopharmacology 2017;42(1):216-241. doi:10.1038/npp.2016.143
[38] Haroon E, Chen X, Li Z, Patel T, Woolwine BJ, Hu XP, et al. Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Transl Psychiatry 2018;8(1):189. doi:10.1038/s41398-018-0241-4
[39] Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 2011;35(3):537-55. doi:10.1016/j.neubiorev.2010.06.006
[40] Gold MS, Blum K, Febo M, Baron D, Modestino EJ, Elman I, et al. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. Front Biosci (Schol Ed) 2018;10(2):309-325. doi:10.2741/s518
[41] Jacobson LH, Vlachou S, Slattery DA, Li X, Cryan JF. The Gamma-Aminobutyric Acid B Receptor in Depression and Reward. Biol Psychiatry 2018;83(11):963-976. doi:10.1016/j.biopsych.2018.02.006
[42] Browne CA, Wulf H, Lucki I. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder. Handb Exp Pharmacol 2022;271:493-524. doi:10.1007/164_2020_432
[43] Jacobson ML, Wulf HA, Browne CA, Lucki I. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. Psychopharmacology (Berl) 2020;237(12):3715-3728. doi:10.1007/s00213-020-05649-y
[44] Cardona-Acosta AM, Bolaños-Guzmán CA. Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine. Neuropharmacology 2023;225:109374. doi:10.1016/j.neuropharm.2022.109374
[45] Rincón-Cortés M, Grace AA. Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress. Behav Brain Res 2020;379:112367. doi:10.1016/j.bbr.2019.112367
[46] Serretti A. Anhedonia: Current and future treatments. PCN Rep 2025;4(1):e70088. doi:10.1002/pcn5.70088
[47] McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. Clin Psychopharmacol Neurosci 2023;21(4):609-616. doi:10.9758/cpn.23.1081
[48] Blanco J, Quimbaya P, Mena M, Dodd S, Bustos RH. Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder. Expert Rev Neurother 2024;24(9):837-848. doi:10.1080/14737175.2024.2374024
[49] Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs 2021;26(1):63-74. doi:10.1080/14728214.2021.1898588
[50] Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA Jr. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 2015;29(5):596-607. doi:10.1177/0269881114568041
[51] Sterpenich V, Vidal S, Hofmeister J, Michalopoulos G, Bancila V, Warrot D, et al. Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder. Anesthesiology 2019;130(6):923-935. doi:10.1097/ALN.0000000000002667
[52] Derosa S, Misztak P, Mingardi J, Mazzini G, Müller HK, Musazzi L. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response. Prog Neuropsychopharmacol Biol Psychiatry 2024;128:110871. doi:10.1016/j.pnpbp.2023.110871
[53] Hampsey E, Jelen L, Young AH. Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder. Expert Opin Emerg Drugs 2024;29(3):193-204. doi:10.1080/14728214.2024.2345645
[54] Wong S, Le GH, Vasudeva S, Teopiz KM, Phan L, Meshkat S, et al. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review. J Affect Disord 2024;362:816-827. doi:10.1016/j.jad.2024.07.030
[55] Demyttenaere K. Aticaprant, a kappa opioid receptor antagonist, and the recovered 'interest and pleasure' in the concept of major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2025;275(6):1593-1597. doi:10.1007/s00406-024-01851-7
[56] Der-Avakian A, Barnes SA, Markou A, Pizzagalli DA. Translational Assessment of Reward and Motivational Deficits in Psychiatric Disorders. Curr Top Behav Neurosci 2016;28:231-62. doi:10.1007/7854_2015_5004
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Journal of Public Health and Preventive Medicine